JP4823900B2 - ブラキスピラ・ピロシコリ(Brachyspirapilosicoli)またはオルニトバクテリウム・リノテラケアレ(Ornithobacteriumrhinotracheale)に起因する疾患の処置のためのアイブロシン - Google Patents
ブラキスピラ・ピロシコリ(Brachyspirapilosicoli)またはオルニトバクテリウム・リノテラケアレ(Ornithobacteriumrhinotracheale)に起因する疾患の処置のためのアイブロシン Download PDFInfo
- Publication number
- JP4823900B2 JP4823900B2 JP2006518340A JP2006518340A JP4823900B2 JP 4823900 B2 JP4823900 B2 JP 4823900B2 JP 2006518340 A JP2006518340 A JP 2006518340A JP 2006518340 A JP2006518340 A JP 2006518340A JP 4823900 B2 JP4823900 B2 JP 4823900B2
- Authority
- JP
- Japan
- Prior art keywords
- ibrosin
- feed
- pharmaceutically acceptable
- acceptable salt
- ornithobacterium rhinotracheale
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
- 201000010099 disease Diseases 0.000 title claims description 27
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 title claims description 27
- 241001135620 Ornithobacterium rhinotracheale Species 0.000 title claims description 26
- 238000011282 treatment Methods 0.000 title description 17
- 241000510930 Brachyspira pilosicoli Species 0.000 claims description 21
- 244000144977 poultry Species 0.000 claims description 19
- 150000003839 salts Chemical class 0.000 claims description 17
- OLLSDNUHBJHKJS-XKORHJEPSA-N [(2s,3s,4r,6s)-6-[(2r,3s,4r,5r,6r)-6-[[(4r,5s,6s,7r,9r,11e,13e,15r,16r)-4-acetyloxy-16-ethyl-15-[[(2r,3r,4r,5r,6r)-5-hydroxy-3,4-dimethoxy-6-methyloxan-2-yl]oxymethyl]-5,9,13-trimethyl-2,10-dioxo-7-(2-oxoethyl)-1-oxacyclohexadeca-11,13-dien-6-yl]oxy]-4-(d Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O.O([C@@H]1[C@@H](C)O[C@H]([C@@H]([C@H]1N(C)C)O)O[C@@H]1[C@@H](C)[C@H](OC(C)=O)CC(=O)O[C@@H]([C@H](/C=C(\C)/C=C/C(=O)[C@H](C)C[C@@H]1CC=O)CO[C@H]1[C@@H]([C@H](OC)[C@H](O)[C@@H](C)O1)OC)CC)[C@H]1C[C@@](C)(O)[C@@H](OC(=O)CC(C)C)[C@H](C)O1 OLLSDNUHBJHKJS-XKORHJEPSA-N 0.000 claims description 16
- 238000000034 method Methods 0.000 claims description 13
- 235000020188 drinking water Nutrition 0.000 claims description 9
- 239000003651 drinking water Substances 0.000 claims description 9
- 238000000338 in vitro Methods 0.000 claims description 5
- 241000186216 Corynebacterium Species 0.000 claims 1
- 241001465754 Metazoa Species 0.000 description 19
- 241000282887 Suidae Species 0.000 description 18
- 235000013594 poultry meat Nutrition 0.000 description 18
- 239000000203 mixture Substances 0.000 description 15
- 239000003814 drug Substances 0.000 description 13
- 208000015181 infectious disease Diseases 0.000 description 13
- 230000002265 prevention Effects 0.000 description 12
- 239000002253 acid Substances 0.000 description 10
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical class CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 9
- 239000003242 anti bacterial agent Substances 0.000 description 9
- 230000000694 effects Effects 0.000 description 9
- 238000009472 formulation Methods 0.000 description 9
- 241000894006 Bacteria Species 0.000 description 8
- 229940088710 antibiotic agent Drugs 0.000 description 8
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 8
- 230000003115 biocidal effect Effects 0.000 description 7
- 239000003120 macrolide antibiotic agent Substances 0.000 description 7
- 239000007787 solid Substances 0.000 description 7
- 241000282898 Sus scrofa Species 0.000 description 6
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical class OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 6
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical class OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 5
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 5
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 5
- 239000004182 Tylosin Substances 0.000 description 5
- 239000008186 active pharmaceutical agent Substances 0.000 description 5
- 239000000654 additive Substances 0.000 description 5
- 235000013312 flour Nutrition 0.000 description 5
- 229960004059 tylosin Drugs 0.000 description 5
- 241000271566 Aves Species 0.000 description 4
- 241000589893 Brachyspira hyodysenteriae Species 0.000 description 4
- 206010012735 Diarrhoea Diseases 0.000 description 4
- 241000204031 Mycoplasma Species 0.000 description 4
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 4
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 4
- 150000007513 acids Chemical class 0.000 description 4
- 239000007864 aqueous solution Substances 0.000 description 4
- XBDQKXXYIPTUBI-UHFFFAOYSA-N dimethylselenoniopropionate Chemical class CCC(O)=O XBDQKXXYIPTUBI-UHFFFAOYSA-N 0.000 description 4
- 238000004519 manufacturing process Methods 0.000 description 4
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 4
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 4
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 4
- 238000002360 preparation method Methods 0.000 description 4
- 238000012360 testing method Methods 0.000 description 4
- WBPYTXDJUQJLPQ-VMXQISHHSA-N tylosin Chemical class O([C@@H]1[C@@H](C)O[C@H]([C@@H]([C@H]1N(C)C)O)O[C@@H]1[C@@H](C)[C@H](O)CC(=O)O[C@@H]([C@H](/C=C(\C)/C=C/C(=O)[C@H](C)C[C@@H]1CC=O)CO[C@H]1[C@@H]([C@H](OC)[C@H](O)[C@@H](C)O1)OC)CC)[C@H]1C[C@@](C)(O)[C@@H](O)[C@H](C)O1 WBPYTXDJUQJLPQ-VMXQISHHSA-N 0.000 description 4
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 3
- 241000272517 Anseriformes Species 0.000 description 3
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 3
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 3
- 235000010469 Glycine max Nutrition 0.000 description 3
- 241001148567 Lawsonia intracellularis Species 0.000 description 3
- KDYFGRWQOYBRFD-UHFFFAOYSA-N Succinic acid Chemical class OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 description 3
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 3
- 229930194936 Tylosin Natural products 0.000 description 3
- 235000011054 acetic acid Nutrition 0.000 description 3
- 230000000996 additive effect Effects 0.000 description 3
- -1 isovaleryl Chemical group 0.000 description 3
- 229940057995 liquid paraffin Drugs 0.000 description 3
- HCWCAKKEBCNQJP-UHFFFAOYSA-N magnesium orthosilicate Chemical compound [Mg+2].[Mg+2].[O-][Si]([O-])([O-])[O-] HCWCAKKEBCNQJP-UHFFFAOYSA-N 0.000 description 3
- 239000000391 magnesium silicate Substances 0.000 description 3
- 229910052919 magnesium silicate Inorganic materials 0.000 description 3
- 235000019792 magnesium silicate Nutrition 0.000 description 3
- 238000002844 melting Methods 0.000 description 3
- 230000008018 melting Effects 0.000 description 3
- 239000000843 powder Substances 0.000 description 3
- 229940040472 pulmotil Drugs 0.000 description 3
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N silicon dioxide Inorganic materials O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 3
- 229940095064 tartrate Drugs 0.000 description 3
- 235000019375 tylosin Nutrition 0.000 description 3
- 229920001817 Agar Polymers 0.000 description 2
- ULGZDMOVFRHVEP-RWJQBGPGSA-N Erythromycin Chemical compound O([C@@H]1[C@@H](C)C(=O)O[C@@H]([C@@]([C@H](O)[C@@H](C)C(=O)[C@H](C)C[C@@](C)(O)[C@H](O[C@H]2[C@@H]([C@H](C[C@@H](C)O2)N(C)C)O)[C@H]1C)(C)O)CC)[C@H]1C[C@@](C)(OC)[C@@H](O)[C@H](C)O1 ULGZDMOVFRHVEP-RWJQBGPGSA-N 0.000 description 2
- 241000192125 Firmicutes Species 0.000 description 2
- 241000287828 Gallus gallus Species 0.000 description 2
- 229920002153 Hydroxypropyl cellulose Polymers 0.000 description 2
- 241000286209 Phasianidae Species 0.000 description 2
- 241000589970 Spirochaetales Species 0.000 description 2
- 241000187747 Streptomyces Species 0.000 description 2
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 2
- ZSLZBFCDCINBPY-ZSJPKINUSA-N acetyl-CoA Chemical compound O[C@@H]1[C@H](OP(O)(O)=O)[C@@H](COP(O)(=O)OP(O)(=O)OCC(C)(C)[C@@H](O)C(=O)NCCC(=O)NCCSC(=O)C)O[C@H]1N1C2=NC=NC(N)=C2N=C1 ZSLZBFCDCINBPY-ZSJPKINUSA-N 0.000 description 2
- 239000004480 active ingredient Substances 0.000 description 2
- 125000002252 acyl group Chemical group 0.000 description 2
- 239000008272 agar Substances 0.000 description 2
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 2
- 230000001580 bacterial effect Effects 0.000 description 2
- 230000037396 body weight Effects 0.000 description 2
- 239000000969 carrier Substances 0.000 description 2
- 210000002421 cell wall Anatomy 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- 235000013330 chicken meat Nutrition 0.000 description 2
- 235000015165 citric acid Nutrition 0.000 description 2
- 239000012895 dilution Substances 0.000 description 2
- 238000010790 dilution Methods 0.000 description 2
- 230000006806 disease prevention Effects 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 239000000945 filler Substances 0.000 description 2
- 239000001863 hydroxypropyl cellulose Substances 0.000 description 2
- 235000010977 hydroxypropyl cellulose Nutrition 0.000 description 2
- 238000011534 incubation Methods 0.000 description 2
- 239000004615 ingredient Substances 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- 230000000968 intestinal effect Effects 0.000 description 2
- 239000012669 liquid formulation Substances 0.000 description 2
- 229940041033 macrolides Drugs 0.000 description 2
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 2
- 230000003287 optical effect Effects 0.000 description 2
- 239000000546 pharmaceutical excipient Substances 0.000 description 2
- 230000035790 physiological processes and functions Effects 0.000 description 2
- 235000019260 propionic acid Nutrition 0.000 description 2
- IUVKMZGDUIUOCP-BTNSXGMBSA-N quinbolone Chemical class O([C@H]1CC[C@H]2[C@H]3[C@@H]([C@]4(C=CC(=O)C=C4CC3)C)CC[C@@]21C)C1=CCCC1 IUVKMZGDUIUOCP-BTNSXGMBSA-N 0.000 description 2
- 210000002966 serum Anatomy 0.000 description 2
- 239000000377 silicon dioxide Substances 0.000 description 2
- 239000011975 tartaric acid Substances 0.000 description 2
- 235000002906 tartaric acid Nutrition 0.000 description 2
- ACMKUBBQEKIEMK-AWEZNQCLSA-N (2s)-2-[acetyl(3-methylbutanoyl)amino]-3-(4-hydroxyphenyl)propanoic acid Chemical compound CC(C)CC(=O)N(C(C)=O)[C@H](C(O)=O)CC1=CC=C(O)C=C1 ACMKUBBQEKIEMK-AWEZNQCLSA-N 0.000 description 1
- XYHKNCXZYYTLRG-UHFFFAOYSA-N 1h-imidazole-2-carbaldehyde Chemical compound O=CC1=NC=CN1 XYHKNCXZYYTLRG-UHFFFAOYSA-N 0.000 description 1
- KDVFRMMRZOCFLS-UHFFFAOYSA-N 2-oxopentanoic acid Chemical compound CCCC(=O)C(O)=O KDVFRMMRZOCFLS-UHFFFAOYSA-N 0.000 description 1
- GWYFCOCPABKNJV-UHFFFAOYSA-M 3-Methylbutanoic acid Natural products CC(C)CC([O-])=O GWYFCOCPABKNJV-UHFFFAOYSA-M 0.000 description 1
- 241000272525 Anas platyrhynchos Species 0.000 description 1
- 241000282472 Canis lupus familiaris Species 0.000 description 1
- 206010051290 Central nervous system lesion Diseases 0.000 description 1
- 208000003322 Coinfection Diseases 0.000 description 1
- 241000272201 Columbiformes Species 0.000 description 1
- 208000035473 Communicable disease Diseases 0.000 description 1
- 206010012741 Diarrhoea haemorrhagic Diseases 0.000 description 1
- 244000068988 Glycine max Species 0.000 description 1
- 206010053759 Growth retardation Diseases 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 206010022678 Intestinal infections Diseases 0.000 description 1
- 102220530096 Linker for activation of T-cells family member 2_P18A_mutation Human genes 0.000 description 1
- 241001293418 Mannheimia haemolytica Species 0.000 description 1
- 241000186359 Mycobacterium Species 0.000 description 1
- 241000288049 Perdix perdix Species 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- XUIMIQQOPSSXEZ-UHFFFAOYSA-N Silicon Chemical compound [Si] XUIMIQQOPSSXEZ-UHFFFAOYSA-N 0.000 description 1
- 235000019764 Soybean Meal Nutrition 0.000 description 1
- 241000187391 Streptomyces hygroscopicus Species 0.000 description 1
- 241000187233 Streptomyces mycarofaciens Species 0.000 description 1
- 241001600136 Streptomyces thermotolerans Species 0.000 description 1
- 241000209140 Triticum Species 0.000 description 1
- 235000021307 Triticum Nutrition 0.000 description 1
- 206010047897 Weight gain poor Diseases 0.000 description 1
- 125000000218 acetic acid group Chemical group C(C)(=O)* 0.000 description 1
- 230000010933 acylation Effects 0.000 description 1
- 238000005917 acylation reaction Methods 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 150000001298 alcohols Chemical class 0.000 description 1
- 150000001408 amides Chemical class 0.000 description 1
- 150000003863 ammonium salts Chemical class 0.000 description 1
- 239000003674 animal food additive Substances 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 230000000844 anti-bacterial effect Effects 0.000 description 1
- 238000011203 antimicrobial therapy Methods 0.000 description 1
- 150000004945 aromatic hydrocarbons Chemical class 0.000 description 1
- 150000007514 bases Chemical class 0.000 description 1
- GWYFCOCPABKNJV-UHFFFAOYSA-N beta-methyl-butyric acid Natural products CC(C)CC(O)=O GWYFCOCPABKNJV-UHFFFAOYSA-N 0.000 description 1
- 238000004166 bioassay Methods 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- KDYFGRWQOYBRFD-NUQCWPJISA-N butanedioic acid Chemical class O[14C](=O)CC[14C](O)=O KDYFGRWQOYBRFD-NUQCWPJISA-N 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 235000013339 cereals Nutrition 0.000 description 1
- UHZZMRAGKVHANO-UHFFFAOYSA-M chlormequat chloride Chemical compound [Cl-].C[N+](C)(C)CCCl UHZZMRAGKVHANO-UHFFFAOYSA-M 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 239000000356 contaminant Substances 0.000 description 1
- 235000021051 daily weight gain Nutrition 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 230000007423 decrease Effects 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 230000018044 dehydration Effects 0.000 description 1
- 238000006297 dehydration reaction Methods 0.000 description 1
- 238000003113 dilution method Methods 0.000 description 1
- 208000001848 dysentery Diseases 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 229960003276 erythromycin Drugs 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- 150000002170 ethers Chemical class 0.000 description 1
- 239000012467 final product Substances 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 239000012458 free base Substances 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 231100000001 growth retardation Toxicity 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 208000027909 hemorrhagic diarrhea Diseases 0.000 description 1
- 238000004128 high performance liquid chromatography Methods 0.000 description 1
- 239000003906 humectant Substances 0.000 description 1
- 235000011167 hydrochloric acid Nutrition 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 229910052500 inorganic mineral Inorganic materials 0.000 description 1
- 244000000053 intestinal parasite Species 0.000 description 1
- UYVZIWWBJMYRCD-ZMHDXICWSA-N isovaleryl-CoA Chemical compound O[C@@H]1[C@H](OP(O)(O)=O)[C@@H](COP(O)(=O)OP(O)(=O)OCC(C)(C)[C@@H](O)C(=O)NCCC(=O)NCCSC(=O)CC(C)C)O[C@H]1N1C2=NC=NC(N)=C2N=C1 UYVZIWWBJMYRCD-ZMHDXICWSA-N 0.000 description 1
- 150000002576 ketones Chemical class 0.000 description 1
- 210000002429 large intestine Anatomy 0.000 description 1
- 231100000518 lethal Toxicity 0.000 description 1
- 230000001665 lethal effect Effects 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 235000012054 meals Nutrition 0.000 description 1
- 244000005700 microbiome Species 0.000 description 1
- 230000001617 migratory effect Effects 0.000 description 1
- 239000011707 mineral Substances 0.000 description 1
- 150000007522 mineralic acids Chemical class 0.000 description 1
- 230000008450 motivation Effects 0.000 description 1
- 239000013642 negative control Substances 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 235000005985 organic acids Nutrition 0.000 description 1
- 238000007911 parenteral administration Methods 0.000 description 1
- 244000052769 pathogen Species 0.000 description 1
- 239000003208 petroleum Substances 0.000 description 1
- 239000008194 pharmaceutical composition Substances 0.000 description 1
- 239000013641 positive control Substances 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000000241 respiratory effect Effects 0.000 description 1
- 208000023504 respiratory system disease Diseases 0.000 description 1
- 239000012266 salt solution Substances 0.000 description 1
- 150000004760 silicates Chemical class 0.000 description 1
- 229910052710 silicon Inorganic materials 0.000 description 1
- 239000010703 silicon Substances 0.000 description 1
- 210000000813 small intestine Anatomy 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 239000004455 soybean meal Substances 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 239000007921 spray Substances 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 125000001424 substituent group Chemical group 0.000 description 1
- 239000001384 succinic acid Substances 0.000 description 1
- 235000011044 succinic acid Nutrition 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 150000003892 tartrate salts Chemical class 0.000 description 1
- JTSDBFGMPLKDCD-XVFHVFLVSA-N tilmicosin Chemical compound O([C@@H]1[C@@H](C)[C@H](O)CC(=O)O[C@@H]([C@H](/C=C(\C)/C=C/C(=O)[C@H](C)C[C@@H]1CCN1C[C@H](C)C[C@H](C)C1)CO[C@H]1[C@@H]([C@H](OC)[C@H](O)[C@@H](C)O1)OC)CC)[C@@H]1O[C@H](C)[C@@H](O)[C@H](N(C)C)[C@H]1O JTSDBFGMPLKDCD-XVFHVFLVSA-N 0.000 description 1
- 229960000223 tilmicosin Drugs 0.000 description 1
- 230000000699 topical effect Effects 0.000 description 1
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Chemical class OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 description 1
- 239000000273 veterinary drug Substances 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23K—FODDER
- A23K20/00—Accessory food factors for animal feeding-stuffs
- A23K20/10—Organic substances
- A23K20/195—Antibiotics
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23K—FODDER
- A23K50/00—Feeding-stuffs specially adapted for particular animals
- A23K50/30—Feeding-stuffs specially adapted for particular animals for swines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/65—Tetracyclines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/12—Antidiarrhoeals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
- A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Polymers & Plastics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Zoology (AREA)
- Food Science & Technology (AREA)
- Animal Husbandry (AREA)
- Molecular Biology (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Tropical Medicine & Parasitology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Birds (AREA)
- Pulmonology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Fodder In General (AREA)
- Medicinal Preparation (AREA)
- Feed For Specific Animals (AREA)
Description
水溶液に作成した20部のアイブロシンAPI(活性の薬品成分(active pharmaceutical ingredient))を80部のダイズミールと混合して、その混合物を噴霧乾燥して、1000kgあたり200kgのアイブロシン活性を有する飼料の固体添加物を得る。この処方物をブタおよび家禽の飼料に添加して、最終飼料1000kgあたり25〜200gのアイブロシンという飼料中アイブロシン濃度を得ることができる。
25部のアイブロシン20%と50部の水和ケイ酸マグネシウム(不活性シリカ)、24部の小麦粉飼料および1部の流動パラフィンEPとを粉末混合物として混合して、1000kgあたり50kgのアイブロシン活性を有する飼料についての固体添加物を得る。この処方物は、実施例1と同様に、ブタおよび家禽の飼料に用いられ得る。
実施例2に用いられるような5部のアイブロシン20%と40部の水和ケイ酸マグネシウム、54部の小麦粉飼料および1部の流動パラフィンEPとを粉末混合物として混合して、1000kgあたり10kgのアイブロシン活性を有する飼料についての固体添加物を得る。この処方物は、実施例1と同様に、ブタおよび家禽の飼料に用いられ得る。
アイブロシンを水に溶解して、ブタまたは家禽の飲料水に用いるための80〜90%のアイブロシン活性を有する水溶液を得る。この処方物を飲料水に添加して、飲料水中のアイブロシン濃度を飲料水200リットルあたり25〜100gの範囲にさせる。
80%w/wより多い酒石酸アイブロシンを含むアイブロシンAPIを
アイブロシンAPI 163〜169kg
ヒドロキシプロピルセルロース.欧州薬局方 8.2〜8.5kg
水、欧州薬局方 800〜1200リットル
脱脂ダイズ粉末 720kg
を含む850kgのバッチに混合した。
ペレット化または押し出し成形飼料のための高温処理後の、動物飼料におけるコーティングされたアイブロシン処方物処理安定性は、以下の成分:
アイブロシンFG200(実施例5を参照のこと) 250.0kg
軽質流動パラフィン、欧州薬局方 10.0kg
小麦粉飼料 240.0kg
ポリビニルピロリドン 10.0kg〜100.0kg
海泡石 〜1000.0kgまで
によって1000kgのバッチに生成した(ただし、他のバッチサイズを用いてもよい)。
(Brachyspira pilosicoliに対するアイブロシンの最小阻害濃度(MIC)の決定)
アセチルイソバレリルタイロシンのMICを、抗生物質希釈法を用いてイングランドの種々の地方で種々のブタ集団から単離されたBrachyspira pilosicoliの5つの野外株に対して決定した。各々の単離体の0.2mlの4つの複製物を、0.78〜200μg/mlの抗生物質濃度で調製した寒天プレートに接種した。アセチルイソバレリルタイロシンのMICが既に公知であるBrachyspira hyodysenteriaeのある株(P18A)をコントロールとして用いた。決定されたMICは以下の表に示す。
(MIC(最小阻害濃度)試験を用いるOrnithobacterium rhinotrachealeに対するアイブロシンおよびチルミコシン(tilmicosin)(プルモチル(pulmotil))の試験)
以下の抗生物質を、Ornithobacterium rhinotracheale(OR)の4つの単離体に対して各々試験した:
1)アイブロシン
2)プルモチル
1)568/99
2)587/00
3)33/01
4)1322/01
(各々の抗生物質の必要な濃度をその活性成分に従って算出した)
アイブロシン
81%活性
32μg/ml×2=64μg/ml
64μg/ml×1.23=78.72μg/ml
=0.04g/500ml
プルモチル
25%活性
32μl/ml×2=64μl/ml
64μl/ml×4=256μl/ml
=0.13ml/500ml
抗生物質希釈に対する添加の前の光学密度読み取り(540nm):
1)568/99−1.025
2)587/00−1.045
3)33/01−1.058
4)1322/01−1.081
0.5μg/mlというアイブロシンの濃度によって、試験されたOrnithobacterium rhinotrachealeの単離体の増殖が阻害された。
Claims (10)
- アイブロシンまたはその薬学的に受容可能な塩を投与することにより、ブラキスピラ・ピロシコリ(Brachyspira pilosicoli)に起因するヒト以外の動物の疾患を処置、予防または管理する方法。
- 前記ヒト以外の動物がブタである、請求項1に記載の方法。
- アイブロシンまたはその薬学的に受容可能な塩を、10〜200ppmの割合で飼料へ添加する、請求項1または2に記載の方法。
- アイブロシンまたはその薬学的に受容可能な誘導体を、飼料または飲料水へ添加する、請求項1乃至3のいずれかに記載の方法。
- アイブロシンまたはその薬学的に受容可能な塩を投与することにより、オルニトバクテリウム・リノテラケアレ(Ornithobacterium rhinotracheale)に感染したヒト以外の動物を処置、予防または管理する方法。
- 前記ヒト以外の動物が家禽である、請求項5に記載の方法。
- アイブロシンまたはその薬学的に受容可能な塩を、10〜200ppmの割合での飼料への添加する、請求項5または6に記載の方法。
- アイブロシンまたはその薬学的に受容可能な塩を、飼料または飲料水へ添加する、請求項5乃至7のいずれかに記載の方法。
- インビトロにおけるブラキスピラ・ピロシコリ(Brachyspira pilosicoli)の増殖の予防または軽減のために、アイブロシンまたはその薬学的に受容可能な塩を使用する方法。
- インビトロにおけるオルニトバクテリウム・リノテラケアレ(Ornithobacterium rhinotracheale)の増殖の予防または軽減のために、アイブロシンまたはその薬学的に受容可能な塩を使用する方法。
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GBGB0315629.6A GB0315629D0 (en) | 2003-07-03 | 2003-07-03 | New uses for antibiotic |
GB0315629.6 | 2003-07-03 | ||
PCT/GB2004/002887 WO2005002593A1 (en) | 2003-07-03 | 2004-07-05 | Aivlosin for the treatment of disease due to brachyspira pilosicoli or ornithobacterium rhinotracheale |
Publications (3)
Publication Number | Publication Date |
---|---|
JP2007516945A JP2007516945A (ja) | 2007-06-28 |
JP2007516945A5 JP2007516945A5 (ja) | 2007-09-06 |
JP4823900B2 true JP4823900B2 (ja) | 2011-11-24 |
Family
ID=27741546
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2006518340A Expired - Lifetime JP4823900B2 (ja) | 2003-07-03 | 2004-07-05 | ブラキスピラ・ピロシコリ(Brachyspirapilosicoli)またはオルニトバクテリウム・リノテラケアレ(Ornithobacteriumrhinotracheale)に起因する疾患の処置のためのアイブロシン |
Country Status (11)
Country | Link |
---|---|
US (1) | US20060166905A1 (ja) |
EP (1) | EP1641469A1 (ja) |
JP (1) | JP4823900B2 (ja) |
KR (1) | KR20060027799A (ja) |
CN (2) | CN101879177B (ja) |
BR (1) | BRPI0412288A (ja) |
CA (1) | CA2530922A1 (ja) |
GB (1) | GB0315629D0 (ja) |
MX (1) | MXPA05013703A (ja) |
RU (1) | RU2005140156A (ja) |
WO (1) | WO2005002593A1 (ja) |
Families Citing this family (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2007006130A1 (en) * | 2005-06-16 | 2007-01-18 | Aimleds Corporation | Lighting assembly, heat sink, and handrail incorporating a lighting assembly |
KR101413274B1 (ko) | 2006-07-13 | 2014-07-08 | 캠브리지 엔터프라이즈 리미티드 | 항바이러스제로서의 틸발로신의 용도 |
FR2909558B1 (fr) * | 2006-12-12 | 2009-04-17 | Ceva Sante Animale Sa | Procede de fabrication de premelanges medicamenteux |
CN106361707B (zh) * | 2016-09-30 | 2019-02-26 | 广东温氏大华农生物科技有限公司 | 一种酒石酸泰万菌素颗粒制剂及其制备方法 |
CN107485604A (zh) * | 2017-07-13 | 2017-12-19 | 中牧实业股份有限公司黄冈动物药品厂 | 一种改进的酒石酸泰万菌素可溶性粉及其制备方法 |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS52139088A (en) * | 1976-05-15 | 1977-11-19 | Sanraku Inc | Antibiotics tyrocin derivatives and their preparation |
WO2002032233A2 (en) * | 2000-10-18 | 2002-04-25 | Eco Animal Health Ltd. | Treatment and prophylaxis of diseases and infections of pigs and poultry with aivlosin |
Family Cites Families (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CH619267A5 (ja) * | 1975-08-01 | 1980-09-15 | Sanraku Ocean Co |
-
2003
- 2003-07-03 GB GBGB0315629.6A patent/GB0315629D0/en not_active Ceased
-
2004
- 2004-07-04 US US10/563,210 patent/US20060166905A1/en not_active Abandoned
- 2004-07-05 CA CA002530922A patent/CA2530922A1/en not_active Abandoned
- 2004-07-05 JP JP2006518340A patent/JP4823900B2/ja not_active Expired - Lifetime
- 2004-07-05 CN CN2010101837246A patent/CN101879177B/zh not_active Expired - Lifetime
- 2004-07-05 MX MXPA05013703A patent/MXPA05013703A/es active IP Right Grant
- 2004-07-05 CN CN2004800183986A patent/CN1812796B/zh not_active Expired - Lifetime
- 2004-07-05 RU RU2005140156/15A patent/RU2005140156A/ru not_active Application Discontinuation
- 2004-07-05 EP EP04743233A patent/EP1641469A1/en not_active Withdrawn
- 2004-07-05 WO PCT/GB2004/002887 patent/WO2005002593A1/en active Application Filing
- 2004-07-05 KR KR1020057022633A patent/KR20060027799A/ko not_active Application Discontinuation
- 2004-07-05 BR BRPI0412288-7A patent/BRPI0412288A/pt not_active Application Discontinuation
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS52139088A (en) * | 1976-05-15 | 1977-11-19 | Sanraku Inc | Antibiotics tyrocin derivatives and their preparation |
WO2002032233A2 (en) * | 2000-10-18 | 2002-04-25 | Eco Animal Health Ltd. | Treatment and prophylaxis of diseases and infections of pigs and poultry with aivlosin |
Also Published As
Publication number | Publication date |
---|---|
GB0315629D0 (en) | 2003-08-13 |
CA2530922A1 (en) | 2005-01-13 |
CN1812796A (zh) | 2006-08-02 |
CN101879177A (zh) | 2010-11-10 |
EP1641469A1 (en) | 2006-04-05 |
CN1812796B (zh) | 2010-12-08 |
RU2005140156A (ru) | 2006-08-27 |
JP2007516945A (ja) | 2007-06-28 |
US20060166905A1 (en) | 2006-07-27 |
KR20060027799A (ko) | 2006-03-28 |
MXPA05013703A (es) | 2006-03-08 |
BRPI0412288A (pt) | 2006-09-19 |
CN101879177B (zh) | 2012-10-03 |
WO2005002593A1 (en) | 2005-01-13 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP5001234B2 (ja) | ブタ及び家禽類の疾患及び感染症の治療及び予防 | |
JP4823900B2 (ja) | ブラキスピラ・ピロシコリ(Brachyspirapilosicoli)またはオルニトバクテリウム・リノテラケアレ(Ornithobacteriumrhinotracheale)に起因する疾患の処置のためのアイブロシン | |
AU2002319190B2 (en) | Synergistic antibiotic compositions | |
EP0213692B1 (en) | Use of hygromycin and epihygromycin in the treatment of swine dysentery | |
CN117679362B (zh) | 一种兽用沃尼妙林溶液及其制备方法和应用 | |
TW202102232A (zh) | 咸豐草與其化合物於預防及治療下痢之用途 | |
JPH06128163A (ja) | 合剤による魚類連鎖球菌感染症の予防または治療剤 | |
HU209810B (en) | Process for producing synergetic pharmaceutical composition for preventing and treating bacterial infections of the respiratory system in poultry | |
JPH07330625A (ja) | 成長促進剤 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20070704 |
|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20070704 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20110118 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20110415 |
|
A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20110422 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20110623 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20110719 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20110801 |
|
TRDD | Decision of grant or rejection written | ||
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20110823 |
|
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20110907 |
|
R150 | Certificate of patent or registration of utility model |
Ref document number: 4823900 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20140916 Year of fee payment: 3 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
EXPY | Cancellation because of completion of term |